LivaNova (NASDAQ: LIVN) and Steris (NYSE:STE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Valuation & Earnings
This table compares LivaNova and Steris’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|LivaNova||$1.21 billion||3.25||-$62.78 million||$1.17||69.88|
|Steris||$2.61 billion||2.78||$109.96 million||$2.85||30.05|
This table compares LivaNova and Steris’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Steris pays an annual dividend of $1.24 per share and has a dividend yield of 1.4%. LivaNova does not pay a dividend. Steris pays out 43.5% of its earnings in the form of a dividend. LivaNova has raised its dividend for 8 consecutive years.
Risk and Volatility
LivaNova has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Steris has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Institutional & Insider Ownership
88.5% of LivaNova shares are owned by institutional investors. Comparatively, 89.5% of Steris shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 2.6% of Steris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of current recommendations and price targets for LivaNova and Steris, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LivaNova currently has a consensus price target of $78.17, indicating a potential downside of 4.39%. Steris has a consensus price target of $80.25, indicating a potential downside of 6.30%. Given LivaNova’s higher probable upside, analysts plainly believe LivaNova is more favorable than Steris.
Steris beats LivaNova on 10 of the 17 factors compared between the two stocks.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.